Profile data is unavailable for this security.
About the company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
- Revenue in USD (TTM)2.24m
- Net income in USD-136.67m
- Incorporated2018
- Employees152.00
- LocationCentury Therapeutics Inc25 N 38TH STREET, 11TH FLOORPHILADELPHIA 19104United StatesUSA
- Phone+1 (215) 981-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.centurytx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 229.60m | 449.00 | -- | 5.17 | -- | 3.81 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 231.42m | 121.00 | -- | 1.35 | -- | 64.28 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.54m | 234.41m | 10.00 | -- | 1.97 | -- | -- | -0.6375 | -0.6375 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -22.78 | -36.79 | -25.71 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1123 | -- | -- | -- | 39.47 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 34.16m | -98.43m | 235.39m | 116.00 | -- | -- | -- | 6.89 | -2.35 | -2.35 | 0.8137 | -1.83 | 0.0989 | -- | -- | 294,439.70 | -28.50 | -31.35 | -34.11 | -35.69 | -- | -- | -288.17 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 235.40m | 1.00 | -- | 66.15 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| AC Immune SA | 16.23m | -59.46m | 236.09m | 133.00 | -- | 1.34 | -- | 14.55 | -0.7037 | -0.7037 | 0.1911 | 1.78 | 0.0803 | -- | 1.92 | 122,010.40 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| 2Seventy Bio Inc | 100.39m | -217.57m | 238.08m | 274.00 | -- | 0.9202 | -- | 2.37 | -4.41 | -4.41 | 2.04 | 5.04 | 0.1643 | -- | 5.84 | 366,375.90 | -35.61 | -- | -40.20 | -- | 83.15 | 91.76 | -216.73 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 238.38m | 122.00 | -- | 1.98 | -- | 286.51 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 240.06m | 152.00 | -- | 0.9716 | -- | 107.41 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 240.55m | 185.00 | 11.05 | 4.45 | 7.27 | 1.02 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| XBiotech Inc | 0.00 | -24.56m | 240.87m | 82.00 | -- | 1.10 | -- | -- | -0.8068 | -0.8068 | 0.00 | 7.19 | 0.00 | -- | -- | 0.00 | -10.39 | 31.88 | -10.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.00 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Nektar Therapeutics | 90.12m | -276.06m | 242.38m | 137.00 | -- | 1.93 | -- | 2.69 | -1.46 | -1.46 | 0.4743 | 0.6844 | 0.1626 | 1.91 | 25.08 | 657,824.80 | -49.80 | -31.02 | -55.82 | -34.63 | 62.53 | 78.04 | -306.31 | -372.21 | 6.14 | -21.17 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 247.14m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| Xeris Biopharma Holdings Inc | 163.91m | -62.26m | 247.20m | 377.00 | -- | -- | -- | 1.51 | -0.4525 | -0.4525 | 1.19 | -0.0491 | 0.4914 | 0.9012 | 4.68 | 434,785.20 | -18.66 | -43.60 | -24.99 | -56.57 | 82.52 | 78.23 | -37.98 | -143.08 | 1.23 | -2.01 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| GeneDx Holdings Corp | 202.57m | -175.77m | 249.33m | 1.00k | -- | 1.09 | -- | 1.23 | -7.51 | -7.51 | 8.34 | 8.78 | 0.4454 | 10.03 | 5.40 | 202,566.00 | -38.64 | -- | -49.75 | -- | 44.43 | 11.50 | -86.77 | -121.10 | 2.95 | -- | 0.2425 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 251.30m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Data as of Apr 19 2024. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD
23.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.61m | 5.57% |
| Casdin Capital LLCas of 29 Feb 2024 | 3.21m | 4.95% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.39m | 2.14% |
| Avidity Partners Management LPas of 31 Dec 2023 | 1.36m | 2.09% |
| DAFNA Capital Management LLCas of 31 Dec 2023 | 1.31m | 2.02% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.10m | 1.70% |
| Tang Capital Management LLCas of 31 Dec 2023 | 1.07m | 1.65% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 797.46k | 1.23% |
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 614.09k | 0.95% |
| Geode Capital Management LLCas of 31 Dec 2023 | 468.46k | 0.72% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
